Dr. Steven F. Cocciardi

Oksana A. Shlobin, MD, FCCP, serves as Medical Director for the Pulmonary Hypertension Program and Director of Outreach and Education for the Inova Advanced Lung Disease and Transplant Program at Inova Fairfax Hospital. She is also an Associate Professor of Clinical Medicine at Georgetown University School of Medicine and an Associate Clinical Professor of Medicine at the University of Virginia. Dr. Shlobin is board certified in pulmonary and critical care medicine. Dr. Shlobin has been actively involved in clinical research both during her fellowship and her tenure at Inova. She is co-author of multiple publications, including original research manuscripts, abstracts and book chapters. Her research interests include pulmonary hypertension and interstitial lung diseases. Blog Posts What is Pulmonary Hypertension? Learn the Facts to Breathe Easy (November 2018) Pulmonary Hypertension is Serious. Learn to Spot the Signs (May 2017). Dr. Shlobin is highly rated in 19 conditions, according to our data. Her clinical expertise encompasses Pulmonary Hypertension, Acute Interstitial Pneumonia, Interstitial Lung Disease, Lung Transplant, and Endoscopy.

Schar Chair, Advanced Lung Disease and Lung Transplant Medical Director, Advanced Lung Disease and Lung Transplant Program, Inova Schar Heart and Vascular Professor of Medical Education, University of Virginia, Inova CampusSteven D. Nathan, MD, FCCP, is the medical director of Inova’s Advanced Lung Disease Program and Lung Transplant Program. He is also a professor of medicine at the University of Virginia.Dr. Nathan is board certified in pulmonary diseases, critical care medicine and internal medicine. The author of more than 500 publications, Dr. Nathan is internationally recognized for his expertise in advanced lung diseases. He is co-editor of two books on idiopathic pulmonary fibrosis that provide pulmonologists and other healthcare workers with an up-to-date review of the background and advances in the field: Idiopathic Pulmonary Fibrosis and Guide to Clinical Management of Idiopathic Pulmonary Fibrosis. He also has written original research manuscripts, abstracts, reviews and book chapters. Dr. Nathan is a reviewer for multiple journals and is on the editorial board for the journal, Thorax. He has served on multiple committees, including U.S. Food and Drug Administration advisory boards as well as steering committees for clinical trials in IPF and pulmonary hypertension, where he has also served as chair. Dr. Nathan is a member of several professional medical associations, including the American Thoracic Society, the American College of Chest Physicians, and the International Society for Heart and Lung Transplantation. He has delivered talks and been chairperson of numerous sessions at many national and international conferences. Dr. Nathan is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Idiopathic Pulmonary Fibrosis, Acute Interstitial Pneumonia, Interstitial Lung Disease, Lung Transplant, and Prostatectomy.

Dr. Danoff is an Assistant Professor in the Division of Pulmonary and Critical Care Medicine and Co-Director of the Hopkins Interstitial Lung Disease Clinic. She is a specialist in diseases causing fibrosis or scarring in the lung, particularly those associated with autoimmune diseases including myositis. Dr. Danoff is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Interstitial Lung Disease, Acute Interstitial Pneumonia, Pulmonary Fibrosis, Lung Transplant, and Endoscopy. Dr. Danoff is board certified in American Board Of Internal Medicine.